Xoten CA 75mg/20mg/75mg Tablet is a combination pharmaceutical formulation containing Aspirin (75mg), Rosuvastatin (20mg), and Clopidogrel (75mg), indicated for the prevention and management of cardiovascular diseases. Aspirin, an antiplatelet agent, inhibits cyclooxygenase, thereby reducing thromboxane A2 production and platelet aggregation, which helps prevent arterial thrombosis. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C) and triglycerides while modestly increasing high-density lipoprotein cholesterol (HDL-C), contributing to the reduction of atherosclerotic plaque progression. Clopidogrel, another antiplatelet agent, selectively inhibits the ADP receptor on platelet cell membranes, preventing platelet activation and aggregation. The combined action of these agents provides a synergistic effect in reducing the risk of myocardial infarction, stroke, and other thrombotic cardiovascular events in patients with established coronary artery disease or at high risk of such conditions. Xoten CA is typically prescribed as part of a comprehensive cardiovascular risk management strategy, including lifestyle modification and other pharmacotherapies. Caution is advised in patients with bleeding disorders, hepatic impairment, or hypersensitivity to any component. Regular monitoring of liver function, lipid profile, and bleeding parameters is recommended during therapy.